The Future of Psychedelic Medicine & Ketamine Therapy with Dylan Beynon the CEO of Mindbloom | Maximus Podcast

This episode of the Maximus Podcast is Part 2 of the interview
with Dylan Beynon the CEO of Mindbloom. Dylan talks about his
company, why he started Mindbloom and what they provide for their
patients. Dylan also talks about why they focus on Ketamine
assisted psychotherapy and the neurological affects Ketamine has
on the brain. Also, Dr. Cam and Dylan discuss the future of
telemedicine and give some insights on why psychedelics need to
be more accessible to those suffering from different
psychological disorders such as depression, PTSD, OCD and other
anxiety disorders. 


Get more information about Mindbloom:


https://www.mindbloom.com/


Maximize your testosterone today:


https://tinyurl.com/MTYouTubeOrg